Human Papilloma Virus Testing Market Research Report 2025-2033 Featuring Abbott Laboratories, BioMerieux, Bio-Rad Laboratories, Epigenomics, Siemens Healthineers, Hologic, Qiagen, F. Hoffmann-La Roche
Human Papilloma Virus Testing Market
Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "Human Papilloma Virus Testing Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering.The Human papillomavirus (HPV) Testing Market was USD 1.52 billion in 2024 and is expected to reach USD 3.62 billion by 2033, with a CAGR of 10.11% from 2025 to 2033. The growth is due to increasing awareness of cervical cancer, increased screening programs, and technological advancements in diagnostic technologies in global healthcare systems.
Internationally, the use of HPV testing is increasing with growing awareness regarding prevention of cervical cancer, government-sponsored screening programs, and WHO's initiative to eliminate cervical cancer as a public health issue. Developed countries have embraced HPV-based screening on a large scale, and developing nations are also adopting it, with the support of global health programs. Its high sensitivity and long-term risk prediction make it a method of choice in contemporary gynecological practice.Growth Driver in the Human Papilloma Virus (HPV) Testing Market
Increasing Awareness and Government Screening ProgramsInternational awareness programs and country-level screening programs have increased demand for HPV testing to a large extent. Governments in developed and emerging economies are adopting routine cervical cancer screening guidelines for women aged 30 and older. WHO organizations advocate for HPV testing as a key tool for early detection of cancer.
Greater awareness of HPV-associated cancers and immunization also reinforces demand. These efforts account for early diagnosis, prompt intervention, and overall reduction in HPV-associated disease burden, thus driving the market forward. SEP 2024, The United States, Australia, India, and Japan are rolling out a key initiative to fight cervical cancer across the Indo-Pacific, a preventable disease which is a significant health crisis in the region. This initiative is part of larger announcements made during the Quad Leaders Summit.Technological Breakthroughs in HPV TestingInnovation in diagnostic methods - like PCR, next-generation sequencing, and self-sampling kits - has revolutionized HPV testing by enhancing accuracy, accessibility, and convenience. Automated platforms, multiplex assays, and liquid-based cytology enable quicker turnaround times and large-scale screening. These technologies are particularly precious in resource-poor settings and enable wider adoption in public health systems. Ongoing R&D spending by diagnostic firms serves to improve test sensitivity and affordability, fueling additional market growth. June 2023, The WHO has prequalified a fourth test for human papillomavirus (HPV). Although most HPV infections will clear on their own, a few of the higher-risk types can cause cervical cancer, so HPV testing is important for cervical cancer screening.Rising Prevalence of HPV-Associated Cancers
Growing global incidence of HPV-related cancers, particularly cervical cancer, is a strong market driver. Cervical cancer is the fourth leading female cancer in the world according to the WHO, and the overwhelming majority of cases are caused by high-risk HPV types. Growing cases of cancer have driven the need for early detection strategies, putting HPV testing at the center of preventive medicine.
As healthcare professionals and patients strive for surefire diagnostic measures, HPV testing is also becoming a necessity in women's health care. An estimated 47,984 new cases of cancer occur each year in the United States in areas of the body where human papillomavirus (HPV) commonly occurs.Challenge in the Human Papilloma Virus (HPV) Testing Market
Limited Access in Low-Income CountriesIn spite of worldwide awareness, HPV testing is not readily available in low- and middle-income countries because of a lack of healthcare infrastructure and resources. There are few laboratory facilities, skilled professionals, and regular screening programs in most areas. Cultural taboo and sexual stigma also discourage HPV testing participation. This inequality avoids early diagnosis and enhances the risk of cervical cancer at advanced stages. It is essential to overcome these barriers using cost-effective point-of-care diagnostics and education initiatives for equitable market expansion.Exorbitant Cost of Sophisticated HPV Testing TechnologiesThe price of advanced HPV testing technologies, including PCR-based platforms and DNA sequencing, can be out of reach for healthcare systems and some patients. As developed nations implement these technologies into regular screening, the affordability gap restricts accessibility in resource-scarce settings. In addition, maintenance costs, quality assurance, and specialized staff requirements contribute to higher operating costs for clinics and laboratories. This cost factor hinders mass screening activities, particularly in developing countries.
Key Players Analyzed: Overview, Key Persons, Recent Development & Strategies, Financial Insights
Abbott Laboratories
BioMerieux SA
Bio-Rad Laboratories, Inc.
Epigenomics AG
Siemens Healthineers AG
Hologic Inc
Qiagen NV
F. Hoffmann-La Roche Ltd
Key Attributes:
Report Attribute
Details
No. of Pages
200
Forecast Period
2024 - 2033
Estimated Market Value (USD) in 2024
$1.52 Billion
Forecasted Market Value (USD) by 2033
$3.62 Billion
Compound Annual Growth Rate
10.1%
Regions Covered
Global
Key Topics Covered: 1. Introduction2. Research Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Human Papilloma Virus Testing Market5.1 Historical Market Trends5.2 Market Forecast6. Human Papilloma Virus Testing Market Share Analysis6.1 By Application6.2 By Product6.3 By Technology6.4 By End Use6.5 By Countries7. Application7.1 Cervical Cancer Screening7.2 Vaginal Cancer Screening8. Product8.1 Consumables8.2 Instruments8.3 Services9. Technology9.1 Polymerase chain reaction (PCR)9.2 Liquid-based cytology9.3 Immunodiagnostics9.4 Hybrid Capture9.5 Others10. End Use10.1 Hospitals & Clinics10.2 Laboratories10.3 Others11. Countries11.1 North America11.1.1 United States11.1.2 Canada11.2 Europe11.2.1 France11.2.2 Germany11.2.3 Italy11.2.4 Spain11.2.5 United Kingdom11.2.6 Belgium11.2.7 Netherlands11.2.8 Turkey11.3 Asia-Pacific11.3.1 China11.3.2 Japan11.3.3 India11.3.4 South Korea11.3.5 Thailand11.3.6 Malaysia11.3.7 Indonesia11.3.8 Australia11.3.9 New Zealand11.4 Latin America11.4.1 Brazil11.4.2 Mexico11.4.3 Argentina11.5 Middle East & Africa11.5.1 Saudi Arabia11.5.2 UAE11.5.3 South Africa12. Porter's Five Forces Analysis12.1 Bargaining Power of Buyers12.2 Bargaining Power of Suppliers12.3 Degree of Rivalry12.4 Threat of New Entrants12.5 Threat of Substitutes13. SWOT Analysis13.1 Strength13.2 Weakness13.3 Opportunity13.4 Threat
14. Key Players Analysis
For more information about this report visit https://www.researchandmarkets.com/r/hxq1p6
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Human Papilloma Virus Testing Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Melden Sie sich an, um Ihr Portfolio aufzurufen.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
"I Was Billed Over $2m For A Week In The Hospital": 51 Horrifying Photos That Encapsulate American Healthcare
in America is genuinely dystopian. should not have to advertise for a kidney. this make sense. me again how America is the greatest country in the world? work should 100% be a part of routine or preventative care. should also be able to talk about your child's medical issues at their physical??? absolutely ridiculous to require a subscription on TOP of health insurance you already pay for. Related: people a heart transplant because they can't pay for the meds shouldn't be a thing, because the meds should be covered in the first place. is so, so bleak. is this. healthcare is so expensive and stressful that it's actually making people's mental health WORSE. a horrific cycle... just goes on and on. me to remind you that the inventors of insulin sold the patents for $1 so that everyone who needed it could afford it. 16."But private healthcare means you can choose your doctors!" policy doesn't even make sense unless you view it through a lens of greed. should NOT be a business. Related: can't possibly cost this much for the hospital to treat a rattlesnake bite. the point of an annual physical if not to check in on any issues? medical care should cost $620k. person didn't even receive any medical care and got charged almost $1.5k. someone explain why it costs $316 just to get evaluated over the phone? me how this is "cosmetic" when the person is in pain. HOURS??? are we even paying for? Related: I'm 99% positive "Nancy" is an incompetent AI bot. 28.I will never understand why ambulance rides are so expensive. This was for a few MINUTES-long ride. are literally having to refuse ambulances — that they NEED — because they're so expensive. is ridiculous. should not be legal. with this. companies are dickheads. They want to make it impossible to get a cent from them. 35.I'm asking the same question. is one of the many reasons why we should have universal healthcare that isn't tied to your job. are really out here looking for coupons for medical care, that's how bad it is. is the bad place. is such BS. If you can't read the above, it says: American Insurance (55M) Had a heart attack, died, revived and my cardiologist wouldn't let me leave the hospital without a LifeVest (portable defibulator). It automatically triggers in case of another cardiac incident. I spent two extra days in the hospital because insurance didn't want to approve the LifeVest. That cost the insurance another $20,000ish. They finally relented and let me have a LifeVest. Now, they say they don't have to pay for the LifeVest. Everyone, the American insurance system (read scam) in a single sentence!!! "Your plan doesn't provide coverage for services that are considered investigational or not medically necessary. The fact that a provider may prescribe, order, recommend or approve a service, treatment, medication, or supply does not make it Medically Necessary or a Covered Service, and does not guarantee payment. These terms are defined in the 'Definition' section of your health plan document." Related: is this. If you can't read the above, it says: Diagnosis: I26.99 Oth Pulmonary Embolism W/O Acute Cor PulmonaleDate(s) determined not to be medically necessary: 11/29/2024 - 11/30/2024 The clinical reason for our determination is:You were admitted to the hospital on 11/29/2024. The reason is blood clot to lung. We read the medical records given to us. We read the guidelines for a hospital stay. This stay does not meet the guidelines. You did not have to be admitted as an inpatient in the hospital for this care. The reason is you were watched closely in the hospital. You were stable. You had tests that did not show any problems that needed inpatient only treatment. The records showed your blood pressure was not too low. You did not need a breathing machine. You could have gotten the care you needed without being admitted inpatient at the hospital. The hospital inpatient admission is not covered. We let the hospital know that it is not covered. insurance isn't going to approve life-saving medicine, what's even the point of having insurance? was this $528??? (After insurance, too!) should not cost $15/capsule. one should have to go without life-saving care because they don't want to have to live for a medical bill. is just completely unhinged. should not be this expensive. good insurance can be great, but tell me why it's almost $40k to begin with??? healthcare is a scam. is so predatory. are you supposed to afford these rates at $9/hour? Never mind the deductibles and copays? finally, this is just genuinely bonkers. The entire system needs to change. Also in In the News: Also in In the News: Also in In the News:
Yahoo
37 minutes ago
- Yahoo
Doctorshire Announces UK-Wide Release of Its Private Healthcare Booking Platform
London, United Kingdom--(Newsfile Corp. - August 3, 2025) - Doctorshire announced the nationwide release of its private healthcare booking platform, giving patients across England, Scotland, Wales, and Northern Ireland a straightforward way to find specialists and confirm appointments online at no charge. The rollout brings together searchable listings for doctors, dentists, and a wide range of health professionals, with clear profiles and patient feedback to support informed choices. To view an enhanced version of this graphic, please visit: How the platform helps patients Patients can look up providers by specialism, city or region, and participating insurer, then request a time that suits them-without phone queues or email chains. Each listing sets out the clinician's areas of interest, clinic details, and recent reviews, so users can compare options before booking. The site also includes plain-English guides to conditions, procedures, and treatments to help patients prepare for consultations; these resources are for background only and do not replace medical advice. Support for practicesDoctorshire also serves clinics and individual practitioners who wish to reach new patients. Providers can create a profile, keep practice information up to date, and manage appointment enquiries from across the UK. A no-cost trial is available for practices that want to see how the listing and booking tools work before committing. Built for London, available everywhereWhile the service is open to the whole country, Doctorshire maintains a particularly deep roster of specialists in London, reflecting the city's concentration of private clinics. Patients in Manchester, Birmingham, Edinburgh, Cardiff, Belfast, and other hubs get the same experience: clear profiles, reviews, and online booking. Looking AheadThe company's roadmap includes smarter search filters, optional teleconsultation, and closer links with insurers to shorten the time from research to confirmed appointment. These updates are intended to cut admin for practices and make access to care faster for patients. About connects patients with private doctors, dentists, and health specialists across the United Kingdom. The platform offers free online booking, open provider profiles, and patient reviews to help people choose the right clinician, while giving practices simple tools to grow their presence and manage enquiries. Learn more at Note: Doctorshire does not provide medical advice, diagnosis, or treatment. Patients should always seek guidance from a qualified healthcare professional for medical concerns. Media ContactCompany: DoctorshireEmail: contact@ To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNN
39 minutes ago
- CNN
HHS: How we're fixing the organ transplant system that betrayed America
EDITOR'S NOTE: Thomas Engels is the administrator of the Health Resources and Services Administration at the US Department of Health and Human Services. Organ donation can be a profound last gift of life. I think about the future my grandson will inherit, especially when it comes to something as urgent and deeply personal as organ donation or transplant. If he or someone he loves needs an organ transplant, I want him to know the system is safe, fair and worthy of his trust. Sadly, our US Department of Health and Human Services investigation of the organ transplant system has revealed everyone's worst nightmare: a systemic disregard for the sanctity of life. We found numerous cases of medical providers starting the organ donation process on living patients. In response, we have threatened to shut down a large organ procurement organization unless it implements our corrective action requirements. We have also imposed strict reporting protocols for the organ transplant system and required that families and hospitals receive clear, complete information about the donation process. How did the organ transplant system fail to protect some of our most vulnerable Americans? It operated behind closed doors for decades, dominated by a single private contractor. Too many patients waited for answers that never came, and families whose loved ones' organs were pursued while still alive were left with nowhere to turn when such atrocities occurred. Only a sick system prioritizes profit over patients. That ended thanks to the leadership of President Donald Trump and HHS Secretary Robert F. Kennedy Jr. At the Health Resources and Services Administration (HRSA), we are undertaking a sweeping overhaul of the Organ Procurement and Transplantation Network (OPTN), the entity legally responsible for managing the organ waitlist and allocation nationwide. Our reforms are rooted in two fundamental truths: Patient safety is not optional, and every life is sacred. For far too long, patients, hospital staff or grieving families were forced to report serious safety concerns and misconduct to the very contractor managing the system. This left families unheard, frustrated or even silenced. That era is over. Now, under our new reforms, those concerns can come directly to the regulator HRSA. We brought federal oversight into the heart of the process, making it clear there will be no compromise on safety and accountability. We've also proposed new data requirements for organ procurement organizations (OPOs), requiring full documentation of every step in the donation process, from contact with hospitals to interactions with donor families. These reforms aren't just about performance tracking. They're about restoring safety and dignity to a system that lost sight of both. And when horrifying failures come to light, like the shocking case in Kentucky in which organ procurement was nearly performed on a patient who showed signs of life, we act immediately. For the first time, HRSA issued a corrective action plan to an OPO, and we will not hesitate to do it again. No American should ever have to wonder whether their life will be treated with reverence at the hospital. The systemic failures weren't just operational — they were structural. For nearly 40 years, OPTN was governed by a single private entity: the United Network for Organ Sharing (UNOS). We ended a monopoly that suppressed innovation, enabled conflicts of interest and delayed reform. HRSA conducted a historic national election to establish an independent OPTN Board of Directors. This new board includes transplant surgeons, living donors, organ recipients and advocates, bringing a range of expertise and experience to the forefront of reform. We are also modernizing the transplant system by expanding the pool of best-in-class vendors to expand the capacity and performance of the system. With bipartisan support, HRSA now has the authority to directly collect OPTN registration fees from transplant hospitals, helping sustain long-term reforms and reduce reliance on any single contractor. Our work is informed by conversations with transplant surgeons, patients, donor families, advocates and hospital staff. These voices have made one thing abundantly clear: Change cannot wait. Secretary Kennedy has demanded accountability across HHS, and President Trump has shown unwavering commitment to ending complacency in systems that cost lives. The old system operated behind closed doors. We opened them up. We are building a system that is ethical, transparent and centered on the sacred sanctity of life. There is more work to do, but we are making progress quickly, just like the rest of the Trump administration. We will not rest until every registered organ donor, patient and family have confidence in our nation's transplant system. Because that's what Americans deserve and what every life demands.
